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LETTER OF TRANSMITTAL 
 
To: Project Engineers and Upper Level Management 
From: Project Evaluation Team 
Date: March 14, 2019 
Subject:  Large-Scale Biomanufacturing Facility Design 
 
This letter is a response to the design proposal for a large-scale biomanufacturing facility 
for monoclonal antibody production. Enclosed is the final report for the project tasked. In the 
design brief, it is stated that the biomanufacturing facility should be able to produce product at 
current reported titers of 1 to 2 g/L as well as projected future titers of 5 to 10 g/L. The design 
team was charged with determining whether or not the project was technically feasible and 
economically attractive based on current and future titers. The seed train portion of the project 
was simulated in MatLab using kinetic information while the purification portion of the process 
was simulated in SuperPro Designer. Based on the simulation and additional market information 
provided, an economic analysis was also performed. Upon finishing these analyses, it was 
determined that in both the best-case and worst-case scenarios, the MAb production process is 
both technically feasible and economically attractive. The design team hereby releases this 
























    
Date Submitted: 
















Table of Contents 
1.…Abstract 
2.…Introduction and Design Basis 
4.…Process Description 
5….PFD and Material Balance 
19…Energy Balance and Utility Requirement 
23…Equipment List and Unit Descriptions 
29…Equipment Specification sheets 
30…Equipment Cost Summary 
32…Fixed Capital Investment Summary 
34…Safety, Health, and Environmental Considerations 
36…Process Safety Considerations 
39…Other Important Considerations 

















List of Tables and Figures 
Tables 
3….Table 1: Specific MAb Production Properties 
3….Table 2: Utility Costs 
4….Table 3: Economic Revenue 
6….Table 4: Upstream Stream Table 
6….Table 5: Downstream Stream Table 
20…Table 6: Yearly Utility Usage 
21…Table 7: Yearly Utility Cost 
23…Table 8: Equipment List 
26…Table 9: Equipment Function 
29…Table 10: Equipment Spec Sheet 
30…Table 11: Equipment Cost Summary 
34…Table 12: Additional Safeguards Evaluations and Requirements 
35…Table 13: Inherently Safer Design Application Summary 
37…Table 14: Hazard Identification 
38…Table 15: Potential Consequence Summary 
40…Table 16: Consumable Cost Summary 
41…Table 17: Raw Material Cost Summary 
42…Table 18: Yearly Cost per Optimization Process 
43…Table 19: 20,000 L Cash Flow Table 
44…Table 20: 30,000 L Cash Flow Table 
45…Table 21: NPV and DCFROR per Optimization Process 
46…Table 22: Sensitivity Analysis NPV and DCFROR 







2….Figure 1: Biomanufacturing Process Example 
5….Figure 2: Process Flow Diagram 
11…Figure 3: Seed Train BFD 
11…Figure 4: Production Reactors BFD 
13…Figure 5: Primary Recovery BFD 
15…Figure 6: Protein A Chromatography BFD 
16…Figure 7: Viral Inactivation BFD 
17…Figure 8: Cation Exchange Chromatography BFD 
18…Figure 9: Anion Exchange Chromatography BFD 
33…Figure 10: Installed Equipment Cost 
39…Figure 11: Site Layout 








Enclosed in this report is the feasibility study of a large-scale biomanufacturing facility. 
The study addresses the technical feasibility and economic attractiveness of the production of 
Monoclonal Antibodies from Chinese Hamster Ovary Cells in varying titers ranging from 1g/L 
to 10 g/L of MAb. 
The proposed design follows the manufacturing process explicitly described in the design 
brief. The initial part of the design process that includes the seed train and production bioreactors 
was simulated and optimized in MatLab using the process’ kinetic information. It was 
determined that three simultaneous trains of increasing reactor size up to 30,000 L needed to be 
run in order to achieve the minimum amount of MAb needed per year. The second part of the 
design process that includes the purification train was simulated and optimized in SuperPro 
Designer. It was determined that when the titers increased over 5 g/L, two purification trains are 
required in order to meet recovery specifications. The results from both simulations proved the 
proposed design is technically feasible. The design requires the purchase of multiple types of 
disposable or non-disposable bioreactors, multiple holding and mixing vessels, several resin 
columns, and multiple storage vessels and waste tanks for an initial capital investment of roughly 
$172 million. 
Construction of the facility will begin in 2019 with operation beginning mid-year 2020. 
The plant would operate at the titer 1 g/L starting in 2020 and increase up to the titer of 10 g/L as 
needed. The plant size is designed for up to 10 g/L, so the yearly utility costs are estimated 
around $2,000,000 per year, while the raw materials and consumables costs are around $134 
million per year. The total project evaluation life is 25 years assuming a tax rate of 30%, a 
minimum rate of return of 15%, and an escalation rate of 2%. The production has an annual 
revenue of over $6 billon in 2019 dollars. Using these economic metrics, it was determined that 
the net present value of project is $32 billion and the DCFROR is 22.3%, with a payback period 
of 0.045 years. Based on these results, the project is economically attractive and should continue 
into construction.  
The capital cost of the project has the biggest impact on the economic viability of the 
proposed process.  If the capital cost increases by 25%, the discounted rate of return will be 
17.9%. If the capital cost decreases by 25%, the discounted rate of return is 29.8%. However, 
even during best-case and worst-case analysis, the DCFROR was still greater than the initial rate 







Introduction and Design Basis 
Introduction 
In today’s society, there are many classes of drugs in development, with the two largest 
classes being small molecule compounds and biopharmaceuticals. Small molecule compounds 
are the typical synthetic drugs that come to mind. Biopharmaceuticals are larger compounds that 
have become a major focus in medical drug production due to their many advantages. They are 
considered safer than traditional medications due to the high selectivity of reacting molecules. 
They are also highly effective in treating a variety of diseases and illnesses such as rheumatoid 
arthritis, cancers, and transplant rejection. [1] 
A particular pharmaceutical company has decided to design a large-scale manufacturing 
facility focusing on the production of biologics. They are pursuing biopharmaceuticals due to the 
lucrative return on investment as it is considered a multibillion-dollar industry. Although there is 
a wide range of biopharmaceuticals, the company has decided to solely focus on monoclonal 
antibody production at this time. 
Humanized Monoclonal Antibodies, or more simply MAbs, are part of the 
biopharmaceutical side of drug development known as biologics. Biologics or biomanufacturing 
produces a product derived from discoveries in recombinant DNA technology to manufacture 
biotherapeutic processes. A monoclonal antibody, also known as a “a therapeutic protein,” is one 
of the most common biologics on the market today. MAbs are derived from the manipulation of 
various cells and the subsequent products the engineered cell systems produce. Figure 1 shows a 












                           
   




MAb production is up and coming in the field of biologics and biomanufacturing. Most 
biologic manufacturing processes are relatively similar in that a frozen vial of cells is mixed with 
some sort of chemically defined media allowing the cells to grow and multiply. Production of 
MAbs begins in the upstream process shown in Figure 1 with CHO cells, also known as Chinese 
Hamster Ovary Cells. Once desired amount of MAb has been synthesized, a rigorous purification 
takes place before being sold on the market. 
 
Design Basis 
The task given in the design brief was to design a manufacturing facility that would allow 
production of MAb at current reported titers of 1 to 2 g/L; however, the facility should be able to 
eventually handle production of up to titers of 5 to 10 g/L.  
Listed below in Table 1 are specifications for the specific process outlined in the design brief. 
                                         Table 1: Specific MAb Production Properties 
Specific MAb Production Properties 
Cell Doubling Time 36 hr 
Minimum Glucose Concentration 2 g/L 
MAb Production Rate 25 pg/cell*day 
Yearly MAb Production 1,000 kg 
Starting CHO Vial Size 1 mL 
Starting CHO Cell Amount 1 x 106 cells 
 
Table 2 below lists utility cost outlined in design brief as well as others found from other 
sources. 
Table 2: Utility Cost 
Utility Costs  
Electricity $.05/kWhr 
Sewer $5.00/1,000 gal 
Water $.543/1,000 L 
WFI $1,000/1,000 L 
Steam* $12/MT 
Compressed Air* $2.38/1,000 kg 
Labor* $16.25/hr 
Flare Waste* $112.97/ton 
 






Table 3: Economic Revenue 
Economic Revenue  
Product 2007 Revenue (US$ million) Estimated Quantity (annual kg BDS) 
Enbrel $5,275 1,020 
Remicade $4,975 1,098 
Rituxan/MabTherma $4,600 1,175 
Herceptin $4,046 1,015 
Avastin $3,424 873 
Humira $3,000 121 
Xolair $613 246 
Tysabri $343 51 
Vectibix $170 28 
 
 
Process Flow Diagram and Material Balances 
Figure 2: Process Flow Diagram 
Table 4: Upstream Stream Table 




               In designing this process, the first step in the production of MAbs is the preparation of 
the media that mixes with the biomass, which in this process is CHO cells. There are two types 
of media that can be mixed with the CHO cells, either serum-free powder which requires the 
addition of sterilized water, or liquid media bought directly from a manufacturer. 
               In terms of the process described above and researching both powder and liquid 
chemically defined media, it was determined that liquid media would be the best choice for the 
project. After gathering prices for both types of media, Lonza ProCHO AT serum-free media 
was chosen. Lonza ProCHO AT already contained the L-glutamine needed for the process. 
Lonza also proved to be more economical as the price for the liquid media was cheaper than both 
Lonza and Thermo Fisher powdered media with L-glutamine. 
Seed Train & Production Reactors 
Directly following the media prep portion of the process, the CHO cells and media 
transition to the seed train and production reactor portion of the process. The seed train consists 
of a 500mL T-flask, a 2.2 Roller Bottle, a 100 L Rocking Bioreactor, a 200 L Rocking 
Bioreactor, a 1200 L Disposable Bioreactor, and a 4000 Disposable Bioreactor. The production 























 seed train is shown below in the Figure 3. The production reactors portion of the process is also 
shown below in Figure 4. 
 
Figure 3: Seed Train BFD 
 
Figure 4: Production Reactors BFD 
During the seed train and production reactor process, several assumptions are made. It is 
assumed during the seed train that the production of CHO cells is always in exponential growth. 
The assumption is made based upon the fact that the stationary phase is determined by the 
amount of glucose present. The glucose should not fall below 2 g/L, so it is assumed that the 
stationary phase is never reached. [2] Also, since the CHO cells are transferred into the same 
media, no lag time occurs after the first vial. Since lag time only occurs in the first vial, the 
assumption is made to allow one day for lag time within the process.  
After assumptions were made about the growth of the CHO cells, reactor sizes were 
chosen. After a large literacy search, it showed that reactor volumes are picked arbitrarily or 
based on industry standards. Based on the MAb example in SuperPro Designer and optimization 
methods in MatlLab, it was decided the best sizes for the seed train reactors were the ones listed 
above. It was also assumed the reactors were halfway filled. Disposable reactors in the seed train 
process were chosen as they were cheaper, they prevented contamination, and lowered the 
turnaround time. The removal of the SIP and CIP steps due to the disposable reactor bags helped 
the most with cutting costs and lowering the turnaround time. The assumption was made to allow 
for extra volume to be added to the reactors or for the differing processes that are expected based 
on the project brief.  
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Once all basic assumptions were made, the seed train calculations were done based on 
kinetic models in MatLab software. Kinetics is used so cell density, glucose density, and MAb 
density can be tracked. Chapter 9 in Essentials of Chemical Reaction Engineering and Chapter 3 
in Environmental Biology were used as references in determining kinetic models. The value of 
glucose consumption rate was also found to be 0.422 pg/cell day. [3] The equations used from 
both references are listed below: 
2 = 𝑒𝜇𝑡 
𝑡 = 𝑑𝑜𝑢𝑏𝑙𝑖𝑛𝑔 𝑡𝑖𝑚𝑒 




𝑟𝑔 = 𝜇𝐶𝑐 
𝐶𝑐 = 𝑐𝑒𝑙𝑙 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 
𝐶𝑐𝑜 = 𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑐𝑒𝑙𝑙 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 =
𝑐𝑒𝑙𝑙𝑠
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑚𝑒𝑑𝑖𝑎
=
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The differential equations listed above were coded into MatLab in order to obtain the 
concentrations of glucose, CHO cells, and MAb over time. The Ode45 Solver was used to solve 
for the concentrations with respect to time. Based on the time needed per batch, it was decided 
that in order to reach the production goal of 1,000 kg/yr, three simultaneous batches need to be 
run. This assumption was made based on assuming the seed train cannot be started while one is 
already in progress. 
Based on the results produced from MatLab, several optimization processes were run to 
find the lowest present worth cost of the process. The size of the last reactor in the process was 
varied to determine the cheapest, most efficient production option for the process. Ending reactor 
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sizes of 10,000 L, 20,000 L, and 30,000 L were chosen to test. The following results are found 
below: 
1. If the seed train is stopped at the 10,000 L container, a batch will take 238 hours 
including one day for lag time and one day for purification. Seven simultaneous batches 
would have to run 36 times a year to initially produce 1260 kg of MAb. However, after a 
20% loss only 1008 kg of MAb would be produced. [4] 
2. If the seed train is stopped at the 20,000 L container, a batch will take 274 hours 
including 1 day for lag time and 1 day for purification. Four simultaneous batches would 
have to run 32 times a year to initially produce 1280 kg of MAb. However, after a 20% 
loss only 1024 kg of MAb would be produced. 
3. If the seed train is stopped at the 30,000 L container a batch will take 295 hours including 
1 day for lag time and 1 day for purification. Three simultaneous batches would have to 
run 29 times a year to initially produce 1305 kg of MAb. However, after a 20% loss only 
1044 kg of MAb would be produced. 
 
Primary Recovery  
               After the seed train process of MAb production, the newly produced CHO cells, MAb, 
and media transition to the primary recovery step of the manufacturing process. The primary 
recovery portion of the manufacturing process is to ensure that we are generating as many MAb 
cells as possible while discarding of the unwanted CHO cells and media.  The primary recovery 
portion of the process is shown below in Figure 5.     
   
Figure 5: Primary Recovery BFD 
 
After the 30,000 L bioreactor, the MAb, media, and CHO Cells are held in a 55,000 L storage 
tank prior to going through the centrifuge. This step ensures that all production will pool in one 
place before sending the newly formed MAb cells through the purification process. If production 
is running at titers below 5 g/L, only one of the purification train will be active. If production is 
making titers above 5 g/L, both purification trains will need to be active to achieve the desired 
product. [4] Once everything is in the storage tank, purification begins by sending everything 
through a centrifuge. The centrifuge separates the different layers of material by weight; 
therefore, the heavier layers are pulled down to the bottom to exit in the waste stream. This 
allows for the heavier media and CHO cells to exit in the waste stream while the MAb cells are 
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transported to the filtering step of the primary recovery process. This removes about 80% of the 
CHO cells from the mixture in one step. The contents from the centrifuge are then passed 
through a filter, so any remaining CHO cells are left behind. Once filtering takes place, the 
remaining MAb and media, about 50,000 L total, are pooled in a storage tank before being 
passed through Protein A Chromatography. 
               It is important to note that beginning with the primary recovery process, Steaming-In-
Place (SIP) and Cleaning-In-Place (CIP) take place in both storage tanks and the centrifuge. SIP 
and CIP were not needed before this step as the previous bioreactors were disposable. Both SIP 
and CIP processes are set up by using a flow rate to ensure proper cleanliness for each batch. The 
CIP process is five steps that are set up as follows: water rinse, base rinse, water rinse, acid rinse, 
followed by a final water rinse. [5] It is also important to note that all equipment in the primary 
recovery process is cleaned at the end of each batch before the next batch comes into the primary 
recovery area. Steam in place procedures were based on delivering steam at a flowrate of 1gpm 
from a 2” diameter pipe, based on industry standards. [6] This results in about 10 minutes of 
steaming for most pieces of equipment. CIP follows the standard practice of a 5-step cleaning 
procedure for most pieces of equipment. This process was a water rinse, a base cleanse with 0.5 
M sodium hydroxide, another water rinse, an acid wash with 10 w% phosphoric acid, and a final 
rinse with WFI. These washes used the same flowrate as that of the SIP, with the aid and base 
step using less wash time but recirculating the flow to ensure equal residence time to clean while 
minimizing chemical usage. The total runtime for most CIP processes runs between 50-90 
minutes based on the volume of the equipment, as the caustic and acid washes have residence 
times that need to be met to ensure proper sterilization of the equipment.  
 
Protein A Chromatography 
After primary recovery, the process is then purified by use of a Protein A 
Chromatography column. Protein A Chromatography is performed in a glass column with 
Protein A resin panels made of a variety of staphylococcus bacteria. The process catches the 
product stream while also allowing any previous solvent and impurities to flow past unhindered. 




Figure 6: Protein A Chromatography BFD 
 
Protein A Chromatography contains several elution steps that are intended to remove all 
remaining impurities from the primary recovery step, before flushing the product off the column. 
The column is initially rinsed with a mix of solvents; EDTA disodium, Sodium Chloride, TRIS 
Base, and TRIS HCl. This buffer is mixed and held in the Rinsing Buffer tanks. The column is 
then equilibrated with the same mixture. After that the column is washed with the solvent 
mixture, the production mixture is run over the column, followed by a wash of a sodium citrate 
solution to remove any further impurities from the column. This is mixed and stored in the 
Elution buffer tanks. Finally, an acetic acid wash is run through the column to fully remove all 
the product adhered to the column. This buffer was mixed and held in the column wash buffer 
tanks.   Once all solvents and brine mixtures are run through the column, the column follows a 
different CIP procedure; a caustic wash of .1M NaOH to cleanse the column, followed by a WFI 
wash. The column is also cleaned with a 10% ethyl alcohol mix before being the next batch of 
product. This solution is stored in the regeneration buffer tanks. This process uses 17,500 L of 
the mixed chemical solution, 31 kg of sodium citrate, 172 kg of acetic acid, and 700 kg of ethyl 
alcohol. All of these chemicals have been diluted with WFI.  
By the end of Protein A Chromatography, all media has been removed from the product 
stream. The product stream contains a mixture of MAb, WFI, and acetic acid, which has been 
filtered through a microfiltration device to ensure any new contaminants that might have been 
introduced are now removed. Following the filtration step, the product stream is sent to a holding 






After Protein A Chromatography, the process goes through the virus inactivation stage. In 
the virus inactivation stage, the virus inside of the MAb cells is inactivated. Inactivation is 
completed by pulling WFI to a diafiltration device from the flushing tank to flush it and then 
running the production mixture though it into a holding tank. After the production mixture has 
been moved, it is then transferred back to the original holding tank to then be moved to the virus 
inactivation tank. Within the virus inactivation tank, Polysorbate-80, a detergent, is added to the 
mixture to inactivate any virus within the cells. This ensures the only remaining components 
inside the cells are the desired MAbs. Once virus inactivation is finished, the product stream is 
pulled through a polishing filter to remove any impurities which might have been transferred in 
with the WFI stream or the Polysorbate-80. The product is then transferred to the Cation 
Exchange Chromatography section of the process. This process requires about 0.32 kg of 
Polysorbate-80 per batch.  The Viral Inactivation step of the process is shown below in Figure 7. 
 
Figure 7: Viral Inactivation BFD 
 
Cation Exchange Chromatography 
Once Virus Inactivation is finished, the product stream is then transferred to the Cation 
Exchange Chromatography portion of the process. The column in the Cation Exchange 
Chromatography consists of a resin adhered to the glass column and is designed to specifically 
remove host protein cells, additional leached protein A, and aggregates of the antibodies which 
are no longer useful from the product stream. The resin has negatively charged substrates on the 
resin surface to adhere positively charged impurities while allowing the product to flow past. [9] 




Figure 8: Cation Exchange Chromatography BFD 
Cation Exchange Chromatography contains several elution steps that are intended to 
remove all remaining impurities before flushing the product off the column. The column is first 
washed with a mix of the following solvents: potassium chloride, sodium dihydrogen phosphate, 
potassium dihydrogen phosphate, and sodium chloride. After washing, the column is then 
equilibrated with the same mixture. This buffer solution is held in the wash tanks. After 
equilibration, it is held for a time before the product stream washes over, adhering the impurities. 
The column is then washed with a sodium hydroxide solution from the Elution buffer tank to 
remove some of the impurities followed by a sodium chloride wash from the regeneration tank to 
elute the column. The column is then washed with a sodium chloride and sodium dihydrogen 
phosphate solution from the final washing buffer tank to cleanse the column of any residual 
binding elements. This process uses about 10,000L of the chemical wash mixture, 59 kg of 
sodium hydroxide in the rinse stream, 174 kg of sodium chloride in the elution stream, and 15 kg 
of sodium chloride and 2.8 kg of sodium dihydrogen phosphate in the rinse stream.  
 Once all solvents are run through the column, the column follows the same CIP as the 
Protein A column; that is a caustic wash with 0.1 M NaOH and a WFI rinse, and then washed 
with a 10% weight ethyl alcohol solution from the rinse tank before moving to a storage tank. 
For the column size, this takes about 291 kg of ethyl alcohol per batch. The final product of the 
Cation Exchange Chromatography is held in the storage tank until it is transferred to the Anion 
Exchange Chromatography step of the production process. 
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Anion Exchange Chromatography 
After Cation Exchange Chromatography, the product stream is run through the final 
purification methods, Anion Exchange Chromatography. Anion Exchange Chromatography is 
specifically designed to remove DNA, endotoxins, and leached Protein A from the stream. The 
column consists of a resin adhered to a glass column, with the resin having positively charged 
substrates on the surface to adhere to negatively charged impurities while also allowing the 
product to flow past. [10]  The Anion Exchange Chromatography step of the process is shown 
below in Figure 9.   
 
Figure 9: Anion Exchange Chromatography BFD 
Anion Exchange Chromatography contains several elution steps that are intended to 
remove all remaining impurities before flushing the product off the column. The column is 
eluted with several solvents to remove the impurities. The column is first washed with a mixture 
of sodium chloride, potassium chloride, potassium dihydrogen phosphate, and sodium 
dihydrogen phosphate before being equilibrated with the same mixture from the wash tank. After 
equilibration, it is held for a time before the product stream washes over. Similarly to the Cation 
exchange column, this process involves the product washing over the column unimpaired while 
any impurities adhere to the column. The column is then washed with a mixture of potassium 
dihydrogen phosphate and N-Methyldiethanolamine (MDEA) from the elution buffer tank to 
remove some of the impurities followed by a potassium chloride wash from the regeneration 
buffer tank to further elute the column. Afterwards a TRIS Base solution from the final wash 
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buffer tank is washed over the column to fully rinse any remaining adhering components off the 
column. Once all solvents are run through the column, the column follows the same CIP as the 
previous two columns; a 0.1 M NaOH wash followed by a WFI rinse, and then washed with a 
10% weight ethyl alcohol solution from the rinse solution tank before moving to a storage tank. 
This process uses about 15,000 L of the chemical mixture, 13.5 kg potassium chloride and 2.5 kg 
of MDEA in the wash stream, 260 kg of potassium chloride in the elution stream, 88 kg of TRIS 
Base in the rinse stream, and 436 kg of ethyl alcohol per batch of the process. [10] 
 
Storage 
At this point the product has been purified, filtered, and “polished”. It is now ready to 
store, so it is sent to large tanks and refrigerated to ensure its viability for the required year. This 
cold room is maintained at the –20 degrees Celsius by a glycerol cooling system.  Roughly 20% 
of the product has been lost over the duration of the purification train. This value is pulled from 
literary expectations. [11] 
Waste Disposal and Treatment 
The waste from all steps, including the column solvents, are gathered into a single large 
tank, and then pH tested. The solution is neutralized as needed; however, this is unlikely due to 
the large amount of WFI which is present within the tank. This large volume should dilute the 
solvents to such a large extent that the pH is relatively near neutral. This tank is filtered twice, 
first with an activated carbon filter, and second with a sand microfiltration unit. These are 
designed to remove a majority of the chemicals from the process stream, as these chemicals 
cannot be emptied into the sewer. [12] The only exceptions to this are potassium citrate and 
Polysorbate-80.  This chemical waste is sent to a disposal service, and the cost of disposal is 
noted.  The only exceptions to this compiling tank are the NaOH solutions used in CIP, the 
NaOH washes from the Protein A, Cation Exchange, and Anion exchange operations and the 
phosphoric acid solution used for CIP. These are sent to a separate tank and used to neutralize 
each other. After they are added, the pH is tested and neutralized as needed. After this, the waste 
is then sent to the city drain.  
 
Energy Balance and Utility Requirements 
Table 6 and Table 7 below show both the annual utility usage for the proposed design as 
well as the annual utility cost for the facility respectively. SuperPro Designer gave values for the 
amount of steam usage in MT per year and electricity in kW-hr per year. SuperPro Designer also 
provided the amount of both water and WFI the process uses at each step in the process. Sewer 
values as well as waste sent to the flare per year were given in SuperPro Designer as well. The 
amount of air used per year was calculated based on values given by SuperPro Designer, and the 
number of operators needed was based on the labor calculation given in the book Analysis, 
Synthesis, and Design. Lastly, biohazard waste was calculated assuming each bag in the 





Table 6: Yearly Utility Usage 
Yearly Utility Usage 
 Upstream Primary 
Recovery 
Protein A Viral 
Inactivation 
CEX AEX Storage Total Process 
Steam (MT) 53 54 3,434 862 1,694 7,026 - 13,123 
Electricity (kWhr) 50,333 9 3,581 22,937 6,145 1,897 64,344 149,246 












Sewer (gal) - - - - - - - 52,128,450 
Air(kg) 1,263,724 - - - - - - 1,263,74 
Labor (operators) - - - - - - - 21 
To Flare (ton) - - - - - - - 1.89 






Table 7: Yearly Utility Cost 
Yearly Utility Cost 
 Upstream Primary 
Recovery 
Protein A Viral 
Inactivation 
CEX AEX Storage Total Process 
Steam  $630 $648 $41,208 $10,344 $20,328 $84,312 - $157,470 
Electricity $2,517 $0.43 $179 $1,147 $307 $95 $3,217 $7,462 
Water $70 $48 $33,805 $3,938 $13,063 $56,220 - $107,144 
WFI $113 $78 $154,450 $15,583 $49,540 $219,008 - $438,772 
Sewer - - - - - - - $260,642 
Air $3,008 - - - - - - $3,008 
Labor - - - - - - - $1,023,750 
To Flare - - - - - - - $214 
Biohazard 
Waste 
$171        




Pricing for electricity, WFI, water, and sewer waste were given in the design brief while 
the pricing value of steam at $12/MT was taken from the SuperPro Designer software. Pricing 
for labor was determined by assuming $16.25 per hour, as that was the average salary of a 
pharmaceutical operator per hour. [14] Compressed air was priced at $2.38 per 1000 kg and flare 
waste was calculated as $112.97 per ton. [15] 
The only steam requirements for the plant are for SIP processes, which do not involve a 
transfer of heat to product streams or intermediate streams, but are instead a way to prepare the 
equipment and vessels for the incoming product, removing any detritus or impurities that may 
have accumulated since the previous CIP step. This steam has no effect on process or 
intermediate streams directly, merely cleaning the equipment. Because of this, the steam is 
purchased at the desired pressure and temperature, used to clean the equipment, and sent back 
into the city. This steam has already been optimized, as it was elected to use higher temperature 
steam and larger diameter pipes to minimize the steam flowrate into the equipment while 
maximizing the cleaning capacity of the steam. This is based upon a study done on the heat and 
cleaning capacity relationship of steam for SIP processes [6].  Additionally, this SIP was 
minimized, both through the steam flowrate and the amount of time needed to steam the process 
equipment. 
For the CIP process, the amount of chemicals as well as the volume of water utilized 
were both minimized. This was done after determining that the residence time of the chemicals 
was more necessary to the cleaning process compared to the volume or concentration of 
chemicals. For this reason, 0.5 M sodium hydroxide was selected as the caustic wash for all 
equipment aside from the columns, which used 0.1 M sodium hydroxide due to the more 
sensitive nature of the column resins. [5] Additionally, 10% by weight phosphoric acid was 
selected for the acid wash due to its strong cleaning capacity without reactivity issues such as 
would be included with the use of hydrochloric or sulfuric acid. Due to these considerations, the 
residence time was increased for all the equipment by adding a recirculation step to the cleaning 
of all items. This increased the duration of the CIP step; however, this is not a concern due to the 
large time gap between batches due to the seed train incubation time. This increase in residence 
time led to a full minimization of acid and base requirements, which allowed the time for 
injection to be significantly reduced as well as the flowrate of the chemicals. Additionally, with 
the reduction of acid and base, the flowrate of water rinses and WFI rinse were also able to be 
reduced. It was elected to use water for the initial and intermediate rinses to simply save money 
due to the expense of WFI and use WFI for the final rinse after the acid wash due to the need for 
purity within the equipment.  
This minimization of water, WFI, and chemical usage was economically as well as 
environmentally motivated. It was also decided to minimize waste further by utilizing the acid 
stream and the base stream from the CIP processes to neutralize each other. The waste from the 
CIP of all apparatuses in the process are pooled, which allows an almost total neutralization due 
to the massive volume of WFI and water, as well as the true chemical neutralization reaction, 
which only produces a water soluble salt which is not hazardous to wildlife or the environment, 
and thus can be flushed down the drain. This eliminates any special expense for the disposal of 





Equipment List /Unit Descriptions/Spec Sheet 
 












T-Flask Plastic 500 mL 3 37 14.7  
L-101 
A/B/C/D 
Roller Bottle Plastic 2.2 L 3 37 14.7 
W-101 
A/B/C/D 
Wave Reactor SS316* 100 L 3 37 14.7 
W-102 
A/B/C/D 
Wave Reactor SS316* 200 L 3 37 14.7 
S-101 
A/B/C/D 
Disposable Bioreactor SS316* 1,200 L 3 37 14.7 
S-102 
A/B/C/D 
Disposable Bioreactor SS316* 4,000 L 3 37 14.7 
R-101 
A/B/C/D 
Bioreactor SS316* 10,000 L 3 37 14.7 
R-102 
A/B/C/D 





SS316  55,000 L 1 25 14.7 
N-101 
A/B 
Centrifuge SS316 50,000 L/h 2 25 14.7 
F-101 
A/B 





SS316 55,000 L 
 
2 25 14.7 
M-101 
A/B 
Wash Mixing Tank SS316 20,000 L 2 25 14.7 
H-101 
A/B 
Wash Holding Tank SS316 20,000 L 2 25 14.7 
M-102 
A/B 
Elution Mixing Tank SS316 35,000 L 2 25 14.7 
H-102 
A/B 












SS316 80,000 L 2 25 14.7 
M-104 
A/B 

















Protein A Column Glass 1,570 L 2 25 14.7 
F-102 
A/B 
Dead End Filter SS316* 30 m2 2 25 14.7 
M-105 
A/B 
Filtration Mixing Tank SS316 4,000 L 2 25 14.7 
H-105 
A/B 
Filtration Holding Tank SS316 4,000 L 2 25 14.7 
V-103 
A/B 
Holding Tank SS316 4,000 L 2 25 14.7 
D-101 
A/B 
Diafiltration SS316 40 m2 2 25 14.7 
V-104 
A/B 
Viral Inactivation Tank SS316 4,000 L  2 25 14.7 
F-103 
A/B 
Dead End Filter SS316* 20 m2 2 25 14.7 
M-106 
A/B 
Wash Mixing Tank SS316  4,000 L 2 25 14.7 
H-106 
A/B 
Wash Holding Tank SS316  4,000 L 2 25 14.7 
M-107 
A/B 
Elution Mixing Tank SS316  4,000 L 2 25 14.7 
H-107 
A/B 










SS316 500 L 2 25 14.7 
M-109 
A/B 
Rinse Mixing Tank SS316 10,000 L 2 25 14.7 
H-109 
A/B 
Rinse Holding Tank SS316 10,000 L 2 25 14.7 
M-110 
A/B 
Cleanse Mixing Tank SS316 4,000 L 2 25 14.7 
H-110 
A/B 
Cleanse Holding Tank SS316 4,000 L 2 25 14.7 
C-102 
A/B 
Cation Exchange Column Glass 500 L 2 25 14.7 
V-105 
A/B 
Exchange Holding Tank SS316 2,500 L 2 25 14.7 
M-111 
A/B 
Wash Mixing Tank SS316 5,000 L 2 25 14.7 






Elution Mixing Tank SS316 5,000 L 
 
2 25 14.7 
H-112 
A/B 
Elution Holding Tank SS316 5,000 L 
 










SS316 500 L 
 
2 25 14.7 
M-114 
A/B 
Rinse Mixing Tank SS316 15,000 L 2 25 14.7 
H-114 
A/B 
Rinse Holding Tank SS316 15,000 L 2 25 14.7 
M-115 
A/B 
Cleanse Mixing Tank SS316 5,000 L 2 25 14.7 
H-115 
A/B 
Cleanse Holding Tank SS316 5,000 L  2 25 14.7 
C-103 
A/B 
Anion Exchange Column Glass 1,500 L 
 
2 25 14.7 
V-106 
A/B 
Final Holding Tank SS316  2,500 L 2 25 14.7 
P-101 Storage Tank SS316 4,000 L 29 -20 14.7 
F-104 Activated Carbon Filter SS316 290 m2 1 25 14.7 
F-105 Microfilter SS316 280 m2 1 25 14.7 
B-101 Aqueous Waste Tank SS316 15,000 L 1 25 14.7 




















Table 9: Equipment Function 
Equipment Function 
Unit Number Unit Type Function 
T-101 
A/B/C/D 
T-Flask Promotes growth of CHO Cells and Production of MAb 
R-101 
A/B/C/D 
Roller Bottle Promotes growth of CHO Cells and Production of MAb 
W-101 
A/B/C/D 
Wave Reactor Promotes growth of CHO Cells and Production of MAb 
W-102 
A/B/C/D 
Wave Reactor Promotes growth of CHO Cells and Production of MAb 
S-101 
A/B/C/D 
Disposable Bioreactor Promotes growth of CHO Cells and Production of MAb 
S-102 
A/B/C/D 
Disposable Bioreactor Promotes growth of CHO Cells and Production of MAb 
R-101 
A/B/C/D 
Bioreactor Promotes growth of CHO Cells and Production of MAb 
R-102 
A/B/C/D 
Bioreactor Promotes growth of CHO Cells and Production of MAb 
V-101 
A/B 
Purification Holding Tank Gathering of all of MAb, Media, and CHO Cells from all 
production lines and pool together. 
N-101 
A/B 
Centrifuge Separate the Media and CHO Cells from the MAb 
F-101 
A/B 
Dead End Filter Filter out all of the CHO cells from the process 
V-102 
A/B 
Purification Holding Tank Gathers the product from the primary recovery step of the 




Wash Mixing Tank Mixes buffer for the wash step in the Protein A Column 
H-101 
A/B 
Wash Holding Tank Holds buffer until the wash step in the Protein A Column 
M-102 
A/B 
Elution Mixing Tank Mixes buffer for the elution step in the Protein A Column 
H-102 
A/B 












Cleanse Mixing Tank Mixes buffer for the cleanse step in the Protein A Column 
H-104 
A/B 




Protein A Column Remove majority of impurities form product stream 
F-102 
A/B 






Filtration Mixing Tank Mix water needed for filtration flushing 
H-105 
A/B 
Filtration Wash Holding Hold water used in each filtration flush step 
V-103 
A/B 
Holding Tank Gather post column product to store before next step 
D-101 
A/B 
Diafiltration Filter out majority of acetic acid in product stream, along 
with any remaining sediments 
V-104 
A/B 
Viral Inactivation Tank Deactivate the virus with Polysorbate-80 to ensure all 
remining biological material is only viable Mab 
F-103 
A/B 
Dead End Filter Filter out any sediments or impurities which entered with 
the Polysorbate-80 stream 
M-106 
A/B 
Wash Mixing Tank Mixes buffer for the wash step in the CEX Column 
H-106 
A/B 
Wash Holding Tank Holds buffer until the wash step in the CEX Column 
M-107 
A/B 
Elution Mixing Tank Mixes buffer for the elution step in the CEX Column 
H-107 
A/B 
Elution Holding Tank Holds buffer until the elution step in the CEX Column 
M-108 
A/B 
Regen Mixing Tank Mixes buffer for the regeneration step in the CEX Column 
H-108 
A/B 




Rinse Mixing Tank Mixes buffer for the rinse step in the CEX Column 
H-109 
A/B 
Rinse Holding Tank Holds buffer until the rinse step in the CEX Column 
M-110 
A/B 
Cleanse Mixing Tank Mixes buffer for the cleanse step in the CEX Column 
H-110 
A/B 
Cleanse Holding Tank Holds buffer until the cleanse step in the CEX Column 
C-102 
A/B 
Cation Exchange Column Remove remaining impurities from the product stream, 
specifically host cell protein and aggregates 
V-105 
A/B 




Wash Mixing Tank Mixes buffer for the wash step in the AEX Column 
H-111 
A/B 
Wash Holding Tank Holds buffer until the wash step in the AEX Column 
M-112 
A/B 
Elution Mixing Tank Mixes buffer for the elution step in the AEX Column 
H-112 
A/B 
Elution Holding Tank Holds buffer until the elution step in the AEX Column 
M-113 
A/B 
Regen Mixing Tank Mixes buffer for the regeneration step in the AEX Column 
H-113 
A/B 
Regen Holding Tank Holds buffer until the regeneration step in the AEX 
Column 






Rinse Holding Tank Holds buffer until the rinse step in the AEX Column 
M-115 
A/B 
Cleanse Mixing Tank Mixes buffer for the cleanse step in the AEX Column 
H-115 
A/B 
Cleanse Holding Tank Holds buffer until the cleanse step in the AEX Column 
C-103 
A/B 
Anion Exchange Column Remove any remaining impurities from the product 




Final Holding Tank Gather and hold product stream from column prior to 
sending to storage 
P-101 Storage Tank Stores final product of MAb for up to a year  
F-104 Activated Carbon Filter Remove particulate chemicals which cannot be disposed 
in sewer from waste stream 
F-105 Microfilter Remove all aqueous chemicals which cannot be disposed 
of in the sewer from waste stream  
B-101 Aqueous Waste Tank Store aqueous waste prior to disposal in the sewer 
B-102 Neutralization Waste Tank Store all neutralization waste from CIP steps across entire 




 Table 10: Equipment Spec Sheet 
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Equipment Cost Summary 
Table 11: Equipment Cost Summary 
Equipment Cost Summary 
Quantit
y 








3 W-101 Wave Reactor Skid 
Volume: 100 L 
$255,000 $765,000 1.5 $1,147,500 
3 W-102 Wave Reactor Skid 
Volume: 200 L 
$255,000 $765,000 1.5 $1,147,500 
3 S-101 Disposable Bioreactor Skid 
Volume: 200 L 
$269,316 $807,948 1.5 $1,211,922 
3 S-102 Disposable Bioreactor Skid 
Volume: 4,000 L 
$897,839 $2,693,517 1.5 $4,040,276 
3 R-101 Bioreactor 
Volume: 10,000 L 
$1,738,000 $5,214,000 1.3 $6,778,200 
3 R-102 Bioreactor  
Volume: 30,000 L 
$2,568,000 $7,704,000 1.3 $10,015,200 
1 V-101 Purification Holding Tank 
Volume: 55,000 L 
$430,000 $430,000 1.3 $559,000 
2 N-101 Centrifuge  
Capacity: 50,000 L/h 
$122,000 $244,000 1.5 $366,000 
2 F-101 Dead End Filter: 
Area: 190 m2 
$671,000 $1,342,000 1.5 $2,013,000 
2 V-102 Purification Holding Tank 
Volume: 55,000 L 
$430,000 $860,000 1.3 $1,118,000 
2 M-101 Wash Mixing Tank 
Volume: 20,000 L  
$319,000 $638,000 1.3 $829,400 
2 H-101 Washing Holding Tank 
Volume: 20,000 L 
$319,000 $638,000 1.3 $829,400 
2 M-102 Elution Mixing Tank 
Volume: 35,000 L 
$364,000 $728,000 1.3 $946,400 
2 H-102 Elution Holding Tank 
Volume: 35,000 L 
$364,000 $728,000 1.3 $946,400 
2 M-103 Regen Mixing Tank 
Volume: 80,000 L  
$487,000 $974,000 1.3 $1,266,200 
2 H-103 Regen Holding Tank 
Volume: 80,000 L 
$487,000 $974,000 1.3 $1,266,200 
2 M-104 Cleanse Mixing Tank 
Volume: 10,000 L  
$287,000 $574,000 1.3 $746,200 
2 H-104 Cleanse Holding Tank 
Volume: 10,000 L  
$287,000 $571,000 1.3 $746,200 
2 C-101 Protein A Column 
Volume: 1,570 L 
$558,000 $1,116,000 1.05 $1,171,800 
2 F-102 Dead End Filter $115,000 $230,000 1.5 $345,000 
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Area: 30 m2 
2 M-105 Filtration Mixing Tank 
Volume: 4,000 L 
$258,000 $516,000 1.3 $670,800 
2 H-105 Filtration Wash Holding 
Volume: 4,000 L  
$258,000 $516,000 1.3 $670,800 
2 V-103 Holding Tank 
Volume: 4,000 L 
$258,000 $516,000 1.3 $670,800 
2 D-101 Diafiltration 
Area: 40 m2 
$108,000 $216,000 1.5 $324,000 
2 V-104 Viral Inactivation Tank 
Volume: 4,000 L 
$258,000 $516,000 1.3 $670,800 
2 F-103 Dead End Filter 
Area: 20 m2 
$80,000 $160,000 1.5 $240,000 
2 M-106 Wash Mixing Tank 
Volume: 4,000 L 
$258,000 $516,000 1.3 $670,800 
2 H-106 Wash Holding Tank 
Volume: 4,000  
$258,000 $516,000 1.3 $670,800 
2 M-107 Elution Mixing Tank 
Volume: 4,000 L 
$258,000 $516,000 1.3 $670,800 
2 H-107 Elution Holding Tank 
Volume: 4,000 L 
$258,000 $516,000 1.3 $670,800 
2 M-108 Regen Mixing Tank 
Volume: 500 L  
$193,000 $386,000 1.3 $501,800 
2 H-108 Regen Holding Tank 
Volume: 500 L 
$193,000 $386,000 1.3 $501,800 
2 M-109 Rinse Mixing Tank 
Volume: 10,000 L 
$278,000 $556,000 1.3 $722,800 
2 H-109 Rinse Holding Tank 
Volume: 10,000 L 
$278,000 $556,000 1.3 $722,800 
2 M-110 Cleanse Mixing Tank 
Volume: 4,000 L 
$258,000 $516,000 1.3 $670,800 
2 H-110 Cleanse Holding Tank 
Volume: 4,000 L  
$258,000 $516,000 1.3 $670,800 
2 C-102 Cation Exchange Column 
Volume: 500 L 
$557,000 $1,114,000 1.05 $1,169,700 
2 V-105 Exchange Holding Tank 
Volume: 2,500 L 
$242,000 $484,000 1.3 $629,200 
2 M-111 Wash Mixing Tank 
Volume: 5,000 L 
$266,000 $532,000 1.3 $691,600 
2 H-111 Wash Holding Tank 
Volume: 5,000 L 
$266,000 $532,000 1.3 $691,600 
2 M-112 Elution Mixing Tank 
Volume: 5,000 L  
$266,000 $532,000 1.3 $691,600 
2 H-112 Elution Holding Tank 
Volume: 5,000 L  
$266,000 $532,000 1.3 $691,600 
2 M-113 Regen Mixing Tank $193,000 $386,000 1.3 $501,800 
32 
 
Volume: 500 L 
2 H-113 Regen Holding Tank 
Volume: 500 L 
$193,000 $386,000 1.3 $501,800 
2 M-114 Rinse Mixing Tank 
Volume: 15,000 L 
$301,000 $602,000 1.3 $782,600 
2 H-114 Rinse Holding Tank 
Volume: 15,000 L 
$301,000 $602,000 1.3 $782,600 
2 M-115 Cleanse Mixing Tank 
Volume: 5,000 L 
$266,000 $532,000 1.3 $691,600 
2 H-115 Cleanse Holding Tank 
Volume: 5000 L  
$266,000 $532,000 1.3 $691,600 
2 C-103 Anion Exchange Column 
Volume: 1,500 L 
$561,000 $1,122,000 1.05 $1,1178,100 
2 V-106 Final Holding Tank 
Volume: 2,500 L 
$242,000 $484,000 1.3 $629,200 
29 P-101 Storage Tank 
Volume: 4,000 L  
$6,025 $174,725 1 $174,725 
1 F-104 Activated Carbon Filter 
Area: 290 m2 
$323,000 $323,000 1 $323,000 
1 F-105 Microfilter 
Area: 280 m2 
$316,000 $316,000 1 $316,000 
1 B-101 Aqueous Waste Tank 
Volume: 15,000 L  
$447,967 $447,967 1 $447,967 
1 B-102 Neutralization Waste Tank 






1 * CIP Water System $225,000 $225,000 1 $225,000 
1 * CIP Acid System $225,000 $225,000 1 $225,000 
1 * CIP Base System $225,000 $225,000 1 $225,000 
1 * Vapor Compression 
Distillation System 
$1,040,000 $1,040,000 1 $1,040,000 
1 * Cold Room for Mab 
Storage 
$42,200 $42,200 1 $42,200 
1 * Building $9,218,375 $9,218,375 1 $9,218,375 
Total Capital Cost $171,604,603 
 
Fixed Capital Investment Summary 
The final fixed-capital investment of the proposed design is listed in Table 11 above. 
Table 11 above also contains the name of the equipment as it is shown in the PFD, the 
description of each piece of equipment, the quantity of each piece of equipment, and the unit 
cost, purchase cost, and installed cost. 
In order to achieve the minimum production of MAb per year given in the project brief, it 
is necessary to run three simultaneous upstream processes, so three of each piece of equipment 
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upstream is needed. In addition to the three simultaneous upstream processes needed, two 
purification trains are needed if the process increases to the projected titers of 5 g/L or 10 g/L. 
Purchase costs for everything but the disposable bioreactors, the vapor compression skid, 
the CIP skid, the 4,000 L product storage tanks, the waste tanks, and the cold room for storage 
were pulled directly from the SuperPro Designer software. The disposable bioreactor skids were 
priced using both the SuperPro Designer software and a quote from GE health. A double ratio of 
price and size was used to more accurately price both the 1,200 L and 4,000 L disposable 
bioreactors. In terms of the vapor compression skid, the price was given by a quote from AWS 
Biofarma. The CIP skid’s price was given by Sani Matic and the 4,000 L storage tanks were 
priced as $6,035 per tank. [16]  The prices of the waste tanks were calculated using the costing 
method in Analysis, Synthesis, and Design of Chemical Processes, and the cost of the cold room 
was determined to be $42,200. [18]  Lastly, the cost of a 200,000 square foot building was 
estimated to house our equipment from a brochure from SMET Construction Services.  
Figure 10 below shows a breakdown of the installed equipment costs in terms of sections 
of the process.  The sections of the process include upstream, primary recovery, protein A 
chromatography, viral inactivation, CEX, AEX, storage, and other.  The other category includes 
CIP, WFI treatment, and waste treatment.  This figure shows that storage for the process 
comprises the largest percentage of the installed equipment cost.  This is followed by the 
upstream process, protein A chromatography, AEX, and CEX.  Primary recovery, viral 




















Figure 10: Installed Equipment Cost 
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The quotes given while determining the installation cost for all equipment included both 
purchase and installation cost; however, for equipment pricing taken from SuperPro Designer, 
the installation factors listed above in Table 11 were also taken from the SuperPro Designer 
software. The factor was multiplied by the purchase cost to find the final installation cost. All 
dollars are in 2019 dollars and a contingency and fees rate of 18% was also added for all fixed 
capital to cover the cost of the control system and any other fees associated with the project. 
 
Health, Safety, and Environmental Considerations 
Health and Safety 
1. Safeguards Incorporated in Design 
 There are separated waste disposal tanks to ensure no incompatible chemical 
mixing occurs. [19] 
 All waste is neutralized prior to disposal to ensure environmental compliance. 
[20] 
 The use of mostly mild chemicals is in place to minimize exposure hazards.  
 All streams are diluted for use in columns with WFI to minimize concentration of 
chemicals. 
 The disposable reactor bags are treated as biohazard and disposed of properly. 
[21] 
 
2. Additional Safeguard Evaluations and Requirements 
Table 12 below shows the safeguard techniques used involving sodium 
hydroxide, eco-toxic chemicals, and non-neutralized chemicals throughout the process.  
The evaluation for each hazard is listed followed by the safeguard requirement in place to 
eliminate the hazard.   
Table 12: Additional Safeguard Evaluations and Requirements 
Additional Safeguard Evaluations and Requirements 
Hazard Evaluation Requirement 
Chemical Incompatibility Sodium hydroxide is 
incompatible with most 
everything else 
Store sodium hydroxide waste 
separate from the rest of the 
waste 
Potentially eco-toxic chemicals Some chemicals are toxic to 
wildlife 
Filter out eco-toxic chemicals and 
dispose of them separately 
Non-Neutral chemicals in 
aqueous waste tank 
Need to neutralize chemicals 
before disposal 
Mix sodium hydroxide and 







3. Safety Assessment Summary 
After thorough safety considerations, it was determined that there are no dire 
safety concerns or the potential for project termination to occur. The only major concerns 
regarding the process are the hazards associated with the chemicals and the mixing of the 
chemicals. However, extensive safeguards have been discussed to ensure that hazard 
identification and proper procedures are in place for using any of the chemicals within the 
process. 
Although there are no critical safety concerns that could cause termination, there 
are a few PSM related concerns with the process. The biohazard waste in the upstream 
portion of the process is a critical PSM related concern. During the upstream portion of 
the process, the virus used to produce MAb is not yet inactivated. Due to the health and 
safety concern associated with the inactivated virus, the disposable reactor bags are 
discarded in biohazard waste containers and removed from the facility. Neutralization of 
the waste is also a special PSM related concern of the project. All waste needs to be 
under certain pH values before going down the drain.  
Other than biohazard waste and neutralization of waste, dilution of the chemicals 
entering the process is both a PSM and an RMP concern. Some of the chemicals 
themselves have toxic or corrosive qualities that could cause harm to the operators 
handling them. However, the chemicals are also a potential risk factor to the process 
because if the chemicals are not the correct pH, the entire production of MAb could be 
ruined. Overall, the process design mentioned above is relatively safe and should not be 
denied start up due to any safety concerns. 
4. Inherently Safer Design Application Summary 
Table 13 below includes a brief description of the inherently safer design 
applications involved in the process.  Hazards are identified, followed by the inherent 
safety concept associated with each hazard.  Lastly, the incorporation of the inherently 
safer design for each hazard into the preliminary design is listed. 
 
Table 13: Inherently Safer Design Application Summary 
Inherently Safer Design Application Summary 
Hazard Inherent Safety Concept How Incorporated in Preliminary Design 
Flammability of ethyl alcohol 
stored on site 
Minimization Sealed in an air tight container, storage is 
minimized 
Acetic acid flammability Minimization Sealed in an air tight container, storage is 
minimized 
Compressed air explosive 
pressure release 
Minimization Storage of compressed air is minimized 




Chemical reactivity Moderation Dilution of all chemicals with WFI  
Use of sulfuric acid in process Substitution Replaced with phosphoric acid due to 
sulfuric acid heat of mixing with water 
Use of ethylene glycol in 
process 
Substitution Replaced with glycerol due to toxicity of 
ethylene glycol 
Use of compressed oxygen and 
nitrogen 
Simplification Replace both gas streams with a single 
compressed air line 
 
Environmental 
The chemicals in this process are specifically designed to be used in biological systems, 
so they have very little environmental impact. Some of these chemicals are toxic to wildlife in 
high concentrations.  These chemicals include sodium chloride, acetic acid, tris-base, potassium 
chloride, potassium dihydrogen phosphate, sodium dihydrogen phosphate, sodium hydroxide, 
phosphoric acid, N-methyldiethanolamine.  All of these eco-toxic chemicals are sent to be flared 
for disposal. 
Process Safety Considerations 
Inherently Safer Design 
               The goal of any manufacturing facility, whether biomanufacturing or any other type of 
manufacturing field, is to be inherently safe as well as having an inherently safer design. Within 
the new monoclonal antibody production facility designed in this project, there are ways in 
which it is designed in an inherently safer manner. This section discusses passive, active, and 
procedural methods of the inherently safer design.  
               In any biomanufacturing facility design, there are several strategies in which to ensure 
ISD. In the case of this design, there are several passive strategies that are put into place to 
guarantee the facility is inherently safer. One of the first steps to ensure ISD is to secure the lines 
from the tanks and columns in the biomanufacturing process. This simple task protects the 
facility or workers from leaks or spills of any potentially hazardous materials. Along with 
securing the lines between tanks and columns, allowing ventilation to occur within areas is 
another way to minimize exposure of any toxic chemicals in the event of spills. Closed areas as 
well as closed containers in transportation are other passive methods of ISD design that are 
accounted for in designing an inherently safer facility. [22] 
               Although passive strategies might be the best and easiest way to ensure ISD, there are 
also a few active strategies of ISD that can be used in the proposed design. Having a control 
system for solvent flow is an example of an active strategy of ISD. In the case of an overflow of 
solvent material or in the rare case of a reaction happening due to the leakage of solvent material, 
a control system is in place to help divert solvent or to stop the flow of solvent completely. 
Another example of an active strategy of inherently safer design in the process is the use of 
alarms on material or equipment. The purpose of the alarms is to alert the lab technician or other 
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workers of a dangerous situation happening within the equipment in the facility; therefore, 
creating a sense of inherent safety in the workplace. 
               Besides the passive and active strategies of ISD, the design of the biomanufacturing 
facility also contains a few procedural strategies of inherently safer design. One of the biggest 
procedural strategies of ISD that can be put into place is training. Making sure all technicians 
and employees are trained on the process and equipment is a big portion of ISD. Along with 
training, emergency cleaning methods and venting of certain areas are classified as procedural 
strategies of inherently safer design. While the above safety measures seem daunting, the 
addition of them in the design stage limits the need for later additions which could lead to higher 
operational or capital costs. 
Hazards Identification and Risk Analysis 
Table 14 below indicates the source and hazard involved with each of the hazardous chemicals in 
the process.   
Table 14: Hazard Identification 
Hazard Identification 
Source Hazard 
N-Methyldiethanolamine Corrosivity N-Methyldiethanolamine causes skin, eye, and 
respiratory irritation. 
Potassium Chloride Corrosivity Potassium Chloride causes acute skin and eye 
irritation. 
TRIS Hydrochloride Corrosivity TRIS Hydrochloride causes mild skin, eye, and 
respiratory irritation. 
TRIS Base Reactivity TRIS Base causes mild skin, eye, and respiratory 
irritation. 
Ethyl Alcohol Flammability Ethyl Alcohol has a lower explosive limit of 3.3% 
in air. 
Acetic Acid Flammability Acetic Acid has a lower explosive limit of 4% in 
air.  
Acetic Acid Corrosivity Acetic Acid causes severe skin, eye, and 
respiratory irritation. 
Sodium Chloride Toxicity Sodium Chloride is very dangerous and toxic 
if large quantities are ingested. 
Sodium Citrate Corrosivity Sodium Citrate causes mild skin, eye, and 
respiratory irritation. 
Ethylenediaminetetraacetic acid Corrosivity Ethylenediaminetetraacetic acid causes mild 
skin, eye, and respiratory irritation. 
Sodium Hydroxide Toxicity Sodium Hydroxide causes burning of respiratory 
tract if ingested or inhaled.  
Sodium Hydroxide Corrosivity 
 
Sodium Hydroxide causes severe burning and 
instant irritation with contact to skin and eyes. 
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Phosphoric Acid Toxicity Phosphoric Acid causes a risk of burns and 
permanent tissue damage to digestive tract if 
ingested. 
Phosphoric Acid Corrosivity Phosphoric Acid causes severe burns, ulcers, and 
irreversible eye injury 
Compressed Air Explosive Pressure Release A release of compressed air causes severe physical 
and personnel damage due to the explosion. 
 
Table 15 below shows the consequences of the various chemicals in the process including 
the consequences on equipment damage, environmental compliance, loss of life, disruptions of 
other business units, legal and PR, and community impact.   
Table 15: Potential Consequence Summary 

















low low low - low - 
Potassium Chloride 
Corrosivity 
low low low - low - 
TRIS Hydrochloride 
Corrosivity 
- low - - low - 
TRIS Base Reactivity - low - - low - 
Ethyl Alcohol 
Flammability 
high moderate moderate high high low 
Acetic Acid 
Flammability 
moderate moderate moderate moderate high low 
Acetic Acid Corrosivity moderate moderate low low low - 
Sodium Chloride 
Toxicity 
low low low - low - 
Sodium Citrate 
Corrosivity 
- low - - low - 
Ethylenediaminetetraacet
ic acid Corrosivity 
- moderate - - low - 
Sodium Hydroxide  
Toxicity 
low moderate moderate - moderate low 
Sodium Hydroxide  
Corrosivity 
moderate moderate low low moderate low 
Phosphoric Acid 
Toxicity 









high - high high high low 
 
Siting and Layout of Processes and Equipment 
The layout of the process is divided among several sections. All of the sections are kept 
separate due to the necessity of maintaining quarantine conditions. [23] Cross contamination 
between sections must be strictly avoided due to the risk of contamination of purified product. 
Clean rooms are necessary for both the final product storage and the seed train. The complete 
layout for the process is shown below in Figure 11. 
 
Figure 11: Site Layout 
From Figure11 above, all buffers are prepared and stored in separate locations. Media 
storage is also available before it enters the seed train. Figure 11 also shows that the layout of the 
processing plant follows the same layout of the process itself. Lastly, there are three separate 
storage areas; one for product storage and two for waste storage. [23] 
Other Important Considerations 
In addition to the previously stated safety concerns and considerations, a final 
consideration is the need to control the pH of several streams for use within column washing or 
elution, as well as the pH of the waste storage tanks. The pH of the waste disposal tanks is 
important due to the potential for environmental damage should a non-neutral solution be 
dumped into the water source. The pH of the streams entering the columns needs to be monitored 
and controlled as our product is a biological product, thus it must be ensured that pH remains 
close to biological ranges to prevent damage to the product. Therefore, pH monitors and control 
valves were attached to all the streams to the columns which might result in a very basic or very 
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acidic pH. This way, if the monitor reads a pH too far from the acceptable range of solvents 
coming into contact with the product, which is about 5-9, then the valve will close, preventing 
this stream form contacting the product, and an operator will be dispatched to adjust the chemical 
composition of the stream to return the pH to the acceptable range. Some streams will have a pH 
outside of the safe range, but this is due to the fact that these streams are only used to elute 
impurities from the ion exchange columns, and do not contact the product stream. Thus, the pH 
of any stream contacting the product stream is controlled and monitored.  
Operation Costs 
Listed below in Table 16 are the yearly consumable costs for the process.  Quantity 
values were chosen based on number of batches per a year, as well as volumes of various pieces 
of equipment.  The media and the biohazard waste container unit costs were pulled from Lonza’s 
website and Zoro’s websites respectively.  The CHO cell vial unit cost was found on Thermo 
Fisher Scientific’s manufacturing website.  The rest of the unit cost values were pulled from 
SuperPro Designer. 
Table 16: Consumable Cost Summary 
Consumable Cost Summary 
Consumable Quantity Unit Cost ($) Annual Cost ($) % of Consumable Cost 
500 mL T-flask 87 $5.54 $482 ~0% 
2.2 L Roller Bottle 87 $6.00 $522 ~0% 
Sartorius CultiBag RM 100 87 $840 $73,080 0.06% 
Sartorius CultiBag RM 200 87 $990 $86,130 0.07% 
Sartorius CultiBag RM 1200 87 $6,109 $531,483 0.42% 
Sartorius CultiBag RM 4000 87 $20,363 $1,771,581 1.39% 
Lonza Media 45,000 L $74 / L $96,570,000 75.61% 
Dead End Filter Cartridge 174 $1,000 $174,000 0.15% 
Protein A Resin 3,142 L $7,358 $23,116,992 18.10% 
Viral Inactivation Filter 2 (40 m2) $400/ m2 $31,776 0.02% 
Resin for CEX 1,800 L $1,500 / L $2,700,000 2.11% 
Resin for AEX 1,620 L $1,500 / L $2,430,060 1.90% 
Carbon Activated Filter 1 $116,000 $116,000 0.09% 
Microfilter 1 $112,000 $112,000 0.09% 
Biohazard Waste Container 2 $260/roll $520 ~0% 
CHO Cell Vial 87 $954 $82,998 0.06% 
Total Consumable Cost $127,797,624 100% 
 
The raw materials used throughout the process are listed below in the table 17.  Density 
and unit cost values for acetic acid, ethyl alcohol, sodium chloride, and sodium citrate were 
given in the SuperPro Designer software.  The density and unit costs for the rest of the raw 
materials were pulled from both Sigma Aldrich as well as Lab Depot Inc.  Quantities were 
calculated from values given in the SuperPro Designer software.   
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Table 17: Raw Material Cost Summary 
Raw Materials Cost Summary 









10 wt% Phosphoric Acid 255,461 kg 1.88 $4.66/L $633,209 10.00% 
.1 M Sodium Hydroxide 90,741 kg 1 $4.99/L $452,798 7.15% 
.5 M Sodium Hydroxide 203,000 kg 1.02 $5.18/L $1,031,193 16.28% 
Acetic Acid 5,539 kg - $0.73/kg $4,398 .07% 
EDTA, Sodium 4,089 kg - $171.56/kg $703,449 11.11% 
Ethyl Alcohol 41,383 kg - $0.75/kg $33,698 0.53% 
Sodium Chloride 13,601 kg - $4.00/kg $58,991 0.93% 
Sodium Citrate 899 kg - $10.00/kg $9,787 0.15% 
TRIS Base 4,640 kg - $20.000/kg $92,429 1.46% 
TRIS Hydrochloride 6,148 kg -- $50.00/kg $307,516 4.86% 
Potassium Chloride 7,975 kg - $24.00/kg $191,351 3.02% 
Potassium Dihydrogen 
Phosphate 
46,980 L - $126.00/L $183 ~0% 
Sodium Dihydrogen 
Phosphate 
835 kg - $16.88/kg $14,084 0.22% 
Polysorbate 80 9 kg 1.09 $45.12/kg $384 0.01% 
N-Methyldiethanolamine 75 kg 1.04 $23.61/kg $4,705 0.03% 
Glycerol 29,000 L - $96.50/L $2,798,500 44.18% 
Total Raw Material Cost $6,333,850 100% 
 
The total annual costs for consumables and raw materials are more than $127 million and 
$6.3 million respectively.  The consumables make up 94% of the annual operating cost, and the 
raw materials makes up 5% of the annual operating cost.  The last 1% is utility costs.  
Economic Analysis 
a. Economic Basis 
Construction for this biomanufacturing process and facility will begin in 2019, with 
startup in midyear 2020, so all economic evaluations are completed in terms of 2019 dollars.  
According to a large literature survey a project evaluation life of 25 was chosen, with year 0 in 
2019 and year 25 in 2044.  The process revenue, raw material costs, and utility costs were all 
escalated over the 25-year evaluation period to take into account the change in value of the 
process.  An escalation rate of 2% was deemed acceptable according to a referenced source. [24] 
A hurdle rate of 15% was applied while evaluating this process. [25] Taxes were considered to 
be 30% based on the current tax rate. [26 ] 
The equipment capital cost and the building cost were both acceptable values considered 
for depreciation.  Therefore, MACRS depreciation was calculated for both capital investments.  
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The equipment was depreciated over a 7-year MACRS depreciation schedule, while the building 
was depreciated over a 39-year schedule, with write-off of the remaining depreciation value 
occurring in the final year of project evaluation.  MACRS depreciation schedule was pulled from 
the IRS Publication 946.   
The revenue for this process was calculated using the comparable current marketed drug 
Enbrel.  According to the AIChE design brief, Enbrel was chosen because the dose requirements, 
treatment cost, and production process are very similar to monoclonal antibodies.  The market 
price of Enbrel is $5.17 million per 1 kg of Enbrel sold in 2007 dollars.  This value was scaled up 
using CEPCI values and then multiplied by the production rate of this process in kg per year to 
find our yearly revenue in 2019 dollars. 
In order to determine the optimal operating capacities for this process, the size of the last 
reactor in the seed train section of the process was varied at 20,000 L and 30,000 L.  Each 
process then had unique aspects including required batches per year to meet demand as well as 
sizing and costing for the remainder of the downstream process.  Full simulations and economics 
evaluations were done on each of the two processes to determine which scenario was optimal.   
b. Optimization 
Each of the optimization scenarios had its own set of costs associated with the process.  
The cost variations are detailed below in table 18.  All economic evaluations including 
depreciation, NPV, and DCFROR were calculated using the appropriate values for each process.  
Table 18: Yearly Cost per Optimization Process 
Yearly Cost per Optimization Process 
 20,000 L Process 30,000 L Process 
Fixed Equipment Capital $174,388,110 $162,386,228 
Consumables Cost $127,042,961 $127,714,106 
Raw Material Cost $5,825,691 $6,333,850 
Utility Cost $1,952,657 $1,998,460 
Building Cost $9,218,375 $9,218,375 
 
 Attached below is the cash flow table for the 20,000 L optimization process.  
Table 19: 20,000 L Cash Flow Table 
Attached below is the cash flow table for the 30,000 L optimization process. 























As seen in the cash flow tables, both options are individually economically attractive.  
Both processes have a net present value greater than 0, and a discounted cash flow rate of return 
greater than the hurtle rate value of 15%.  The calculated values are listed below in Table 21. 
Table 21: NPV and DCFROR per Optimization Process 
NPV and DCFROR per Optimization Process 
 20,000 L Process 30,000 L Process 
NPV $31.55 billion $32.19 billion 
DCFROR 20.5% 22.3% 
 
Since both options are individually economically attractive, the optimal operating process 
was determined to be evaluated and presented.  NPV analysis was used to compare the options.  
As seen in the table above, the 30,000 L process has an NPV greater than that of the 20,000 L 
process.  The NPV of the 30,000 L process is $635 million greater than the NPV of the 20,000 L 
process.  Therefore, it was determined that the 30,000 L process was the optimal operating 
condition and process to maximize NPV over the 25-year project life evaluation period. 
The payback period was also calculated for the optimal operating process, to determine 
how long after startup it would take to make back the capital investments.  As seen below in the 
calculation, the payback period was determined to be 0.0445 years, or 2.3 weeks. 
 
Since this is a batch process, and the batches take longer than 2.3 weeks, this payback period is an 
approximation.  The payback period would be 2.3 weeks if the process was being run under continuous 
conditions and the product was being sold continuously as well.  More realistically, the payback period 
would be within the first year.   
c. Sensitivity Analysis-Tornado Chart 
Four variables were chosen to evaluate the sensitivity of the project to determine its 
viability with fluctuations in the economy as well as uncertainties when choosing the evaluation 
period.  The four variables chosen for this process were project life, capital cost, raw material 
cost, and revenue.  The project life was varied by ±5 years due to a wide survey of literature that 
stated that biomanufacturing facilities usually run for 20 to 30 years before a renovation was 
required.  The capital cost and raw material cost were varied by ±25% because this report falls 
somewhere between a study and a preliminary exploration as described in Analysis, Synthesis, 
and Design of Chemical Processes. Lastly, the revenue was varied by ±10% due to the 
difference in the average of the revenue per kg in Table 3 and the selling price of Enbrel.  The 





Table 22: Sensitivity Analysis NPV and DCFROR 
Sensitivity Analysis NPV and DCFROR 
 NPV DCFROR 
Project Life +5 years $32.95 billion 22.3% 
Project Life –5 years $30.79 billion 22.3% 
Capital Cost +25% $32.15 billion 17.9% 
Capital Cost –25% $32.22 billion 29.8% 
Raw Material Cost +25% $32.01 billion 22.2% 
Raw Material Cost –25% $32.36 billion 22.5% 
Revenue +10% $35.49 billion 24.6% 
Revenue –10% $28.88 billion 20.0% 
  
Since all of the NPV values are greater than 0, and every DCFROR value is greater than 
the hurtle rate of 15%, the project is viable even when individual aspects of the economic value 
of the process vary. A tornado chart was made by comparing the adjusted DCFROR values to the 
original case, to weigh the effect each variable has on the discounted cash flow rate of return. 
The tornado chart below, Figure 12, shows that varying the capital cost by ±25% has the greatest 
effect on the DCFROR, followed by varying the revenue by ±10% for the process.  Varying both the raw 
materials by ±10% and the project life by ±5 years resulted in miniscule variances in the DCFROR. 
 





d. Best and Worst Cases 
Best-case and worst-case scenarios were also evaluated to ensure that in the event where 
multiple variances occurred, the process would still be economically attractive. Best-case 
scenario was determined by maximizing revenue, minimizing costs, and expanding the project 
life.  The worst-case scenario was determined by minimizing revenue, maximizing costs, and 
compressing the project life.  As seen below in Table 23, the best and worst-case scenarios are 
described, and the NPV and DCFROR values are presented. 
Table 23: Sensitivity Analysis Variance 
Sensitivity Analysis Variance 
 Best Case Worst Case 
Project Life +5 years -5 years 
Capital Cost -25% +25% 
Raw Material Cost -25% +25% 
Revenue +10% -10% 
NPV $36.55 billion $27.43 billion 
DCFROR 33.0% 15.9% 
 
This table shows that the project is more economically attractive in the best-case scenario 
as expected, but it also shows that even in the worst-case scenario, the NPV is greater than 0 and 
the DCFROR value is greater than the hurtle rate.  This shows that in both the best-case and the 
worst-case scenarios that the project is economically attractive.   
 
Conclusions and Recommendations 
Conclusions 
1. MAb is produced at a significantly higher rate than glucose; therefore, each step reached 
1 g/L of MAb before moving to the next reactor.  
2. Since glucose is consumed at such a slow rate, the starting concentration is always 
assumed to be 6.145 g/L. This assumption is made even though in reality it is changing 
slightly because of the addition of broth to new media. 
3. By economic analysis, the upstream process that ends with a reactor size of 30,000 L 
gives the highest NPV and the greatest DCFROR. 
4. Even with the target concentration of 1 g/L, the process still produces the desired product 
rate of 1,000 kg/yr. 
5. Most of the capital costs incurred during the project will be a one-time purchase and will 
last for the entire project life. 
6. The majority of the cost associated with the project design are incurred in the purification 
train portion of the project design. 
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7. Sartorius CultiBags for disposable reactors and cartridges for filters are replaced after 
every batch of production. 
8. The composition of solutions within the process are mostly Water for Injection (WFI); 
therefore, low amounts of chemicals are used in the process. 
9. Neutralize waste in both tanks, disposing of filtered chemicals at an outside incinerator 
facility.  
Recommendations 
1. Due to massive amounts of WFI, it is recommended to investigate regenerating the WFI, 
if possible, from the aqueous waste tank. 
2. Industry seems to have gone to a 1 mL vial of CHO cells with at least 1 x 107 cells 
instead of the 1 x 106 cells vials mentioned in the project brief.  Look at starting with 
more cells in the seed train. 
3. Recycle steam into water either for use in WFI or the mixing of buffers.  
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APPENDIX B: SuperPro Designer Simulation Screenshots 
 














































































APPENDIX B: SuperPro Designer Material Streams 
 













































































































































































































































































































































































































































































































































































AEX – 30 k 
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